September 2020; 7 (5) Clinical/Scientific NotesOpen Access
COVID-19 in MS
Initial observations from the Pacific Northwest
James D. Bowen, Justine Brink, Ted R. Brown, Elisabeth B. Lucassen, Kyle Smoot, Annette Wundes, View ORCID ProfilePavle Repovic
First published May 26, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000783
James D. Bowen
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
MDJustine Brink
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
DO, MPHTed R. Brown
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
MD, MPHElisabeth B. Lucassen
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
MDKyle Smoot
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
MDAnnette Wundes
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
MDPavle Repovic
From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
MD, PhDCOVID-19 in MS
Initial observations from the Pacific Northwest
James D. Bowen, Justine Brink, Ted R. Brown, Elisabeth B. Lucassen, Kyle Smoot, Annette Wundes, Pavle Repovic
Neurol Neuroimmunol Neuroinflamm Sep 2020, 7 (5) e783; DOI: 10.1212/NXI.0000000000000783
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Letters: Rapid online correspondence
- Reader response: COVID-19 in MS: Initial observations from the Pacific Northwest
- Khichar Shubhakaran, Senior Professor and Head of Department of Neurology, Dr S.N. Medical College (Jodhpur, India)
Submitted September 06, 2020
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North AmericaFrom the COViMS RegistryScott D. Newsome, Anne H. Cross, Robert J. Fox et al.Neurology: Neuroimmunology & Neuroinflammation, August 24, 2021 -
Article
Incidence and Impact of COVID-19 in MSA Survey From a Barcelona MS UnitMaria Sepúlveda, Sara Llufriu, Eugenia Martínez-Hernández et al.Neurology: Neuroimmunology & Neuroinflammation, January 27, 2021 -
Article
A New England COVID-19 Registry of Patients With CNS Demyelinating DiseaseA Pilot AnalysisKelli M. Money, Ashmanie Mahatoo, Soleil Samaan et al.Neurology: Neuroimmunology & Neuroinflammation, August 02, 2021 -
Article
COVID-19 outcomes in MSObservational study of early experience from NYU Multiple Sclerosis Comprehensive Care CenterErica Parrotta, Ilya Kister, Leigh Charvet et al.Neurology: Neuroimmunology & Neuroinflammation, July 09, 2020